US-based generic pharmaceuticals company Padagis announced on Tuesday that it is investing more than USD36m to expand its manufacturing operations in Minneapolis, Minnesota.

This includes the expansion of naloxone nasal spray production and packaging. The move aims to strengthen the company's supply chain resilience, increase production capacity, reduce dependency on overseas shipping, and help keep costs lower and stable for consumers, public health agencies, and community organisations.

Padagis started implementing expansion plans to onshore naloxone production in 2023, which it says represents a significant milestone in its long-term initiative to increase domestic production capacity. The additional capabilities are intended to ensure faster delivery and greater access to its nasal sprays, and specifically naloxone.

The company will commence manufacturing its naloxone in Minnesota before the end of the year.